In vitro release and skin permeation of tacrolimus from monoolein-based liquid crystalline nanoparticles

The objective of the present study was to determine the effect of different ratios of monoolein and oleic acid on in vitro release and skin permeation of tacrolimus from monoolein-based liquid crystalline nanoparticles. The nanoparticles were prepared by sonicating a mixture of melted monoolein, pol...

Full description

Saved in:
Bibliographic Details
Published in:Journal of drug delivery science and technology 2012-01, Vol.22 (6), p.479-484
Main Authors: Thapa, R.K., Baskaran, R., Madheswaran, T., Kim, J.O., Yong, C.S., Yoo, B.K.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Cubosomes
General pharmacology
Hexosomes
Liquid crystalline nanoparticles
Medical sciences
Monoolein
Oleic acid
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Tacrolimus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of the present study was to determine the effect of different ratios of monoolein and oleic acid on in vitro release and skin permeation of tacrolimus from monoolein-based liquid crystalline nanoparticles. The nanoparticles were prepared by sonicating a mixture of melted monoolein, poloxamer 407, oleic acid and tacrolimus to which distilled water was added. Formation of cubosomes and hexosomes was confirmed by transmission electron microscopy and optical microscopy, and average particle size of the formulations was about 150-200 nm. The encapsulation efficiency for tacrolimus in all the formulations was > 99 %. In vitro release of the drug was proportionally reduced by the amount of monoolein used. Addition of oleic acid further reduced the tacrolimus release. The skin permeation was also in agreement with the in vitro release. This study provides a strategy to control the release and skin permeation of tacrolimus from nanoparticles, thus expanding the area of tacrolimus usage.
ISSN:1773-2247
DOI:10.1016/S1773-2247(12)50084-5